THERAPEUTIC ROLE OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE IN PATIENTS WITH TRAUMATIC BRAIN INJURY AND ACUTE CEREBRAL FAILURE SYNDROME
Abstract
Traumatic brain injury (TBI) and acute cerebral insufficiency syndrome are complex medical conditions that pose significant challenges for clinical management due to their high prevalence, diverse pathophysiology, and risk of severe neurological complications. Effective treatment requires a multifaceted approach that not only addresses immediate neurological deficits but also targets secondary injury mechanisms such as oxidative stress, neuroinflammation, and impaired cerebral perfusion.
References
1. Edaravone Acute Brain Injury Study Group. Clinical efficacy of edaravone in patients with acute cerebral infarction. Stroke. 2003;34(4):1035–1040. https://doi.org/10.1161/01.STR.0000067728.16435.7D
2. Shinozuka K, Zhang J, Tsuji K, et al. Neuroprotective effects of edaravone in traumatic brain injury: antioxidant and anti-inflammatory mechanisms. J Neurotrauma. 2017;34(5):1027–1037. https://doi.org/10.1089/neu.2016.4696
3. Maas A.I.R., Menon D.K., Adelson P.D. et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987–1048. https://doi.org/10.1016/S1474-4422(17)30371-X
4. Loane D.J., Kumar A. Microglia in the TBI brain: The good, the bad, and the dysregulated. Exp Neurol. 2016;275(Pt 3):316–327. https://doi.org/10.1016/j.expneurol.2015.08.018
5. Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268(3):1597–1604.
6. Abe K., Aoki M., Tsuji S. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512. https://doi.org/10.1016/S1474-4422(17)30115-1
7. Shibata M., Ohtani R., Ihara M., Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2000;31(8):2132–2138. https://doi.org/10.1161/01.str.31.8.2132
8. Yoshida H., Yanai H. Neuroprotective effects of edaravone: a review. Brain Nerve. 2017;69(6):629–635. (На япон. яз.)
9. Hardiman O., van den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2019;15:117–128. https://doi.org/10.1038/s41582-018-0061-7
10. Zhang L., Zhang Z.G., Zhang C. et al. Edaravone reduces hemorrhagic transformation and mortality after focal cerebral ischemia and reperfusion in rats. Stroke. 2012;43(4):1103–1110. https://doi.org/10.1161/STROKEAHA.111.641134
11. Zhao H., Cheng L., Du X. et al. Edaravone attenuates early brain injury after traumatic brain injury in rats by suppressing apoptosis and oxidative stress. Neurochem Res. 2018;43(12):2489–2499. https://doi.org/10.1007/s11064-018-2641-6
12. Эффективность применения комплексной нейропротекции с применением препарата Эдаравон (Радиксоба-Цоммер) / В. Е. Аваков, Н. К. Ибрагимов, З. Ф. Рамазанова [и др.] // Инновации. Наука. Образование. – 2021. – № 43. – С. 859-870. – EDN RTZPOO.
13. Дадамьянц Н. Г., Красненкова М. Б. Церебральная гемодинамика в прогнозе течения тяжелой черепно-мозговой травмы //Скорая мед. помощь. – 2007. – №. 3. – С. 56.
